ELVN-002 + Trastuzumab + 5-Fluorouracil + Oxaliplatin + Capecitabine + Eribulin + paclitaxel + Leucovorin
Phase 1Active 0 watching 0 views this week๐ค Quiet
28
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HER2-positive Breast Cancer
Conditions
HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification, Colorectal Cancer
Trial Timeline
May 30, 2024 โ Jul 1, 2028
NCT ID
NCT06328738About ELVN-002 + Trastuzumab + 5-Fluorouracil + Oxaliplatin + Capecitabine + Eribulin + paclitaxel + Leucovorin
ELVN-002 + Trastuzumab + 5-Fluorouracil + Oxaliplatin + Capecitabine + Eribulin + paclitaxel + Leucovorin is a phase 1 stage product being developed by Enliven Therapeutics for HER2-positive Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT06328738. Target conditions include HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06328738 | Phase 1 | Active |
Competing Products
20 competing products in HER2-positive Breast Cancer